New SRC/ABL inhibitors for chronic myeloid leukemia therapy show selectivity for T315I ABL mutant CD34(+) cells.
Santucci
Maria Alessandra
MA
Istituto di Ematologia "Lorenzo e Ariosto Seragnoli", Università di Bologna Policlinico S.Orsola, Via Massarenti 9, 40138, Bologna, Italy.
Mancini
Manuela
M
Corradi
Valentina
V
Lacobucci
Ilaria
I
Martinelli
Giovanni
G
Botta
Maurizio
M
Schenone
Silvia
S
D019943:Amino Acid Substitution / Q000235:genetics*; D018952:Antigens, CD34 / Q000378:metabolism*; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D016044:Fusion Proteins, bcr-abl / Q000037:antagonists & inhibitors* / Q000378:metabolism; D006801:Humans; D007928:Lethal Dose 50; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000201:enzymology; D009154:Mutation / Q000235:genetics*; D047428:Protein Kinase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D014410:Tumor Stem Cell Assay; D019061:src-Family Kinases / Q000037:antagonists & inhibitors* / Q000378:metabolism
D018952:Antigens, CD34; D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D016044:Fusion Proteins, bcr-abl; D019061:src-Family Kinases